Janeta Popovici-Muller is SVP Drug Discovery at Rectify Pharmaceuticals, a seed-stage company focused on delivering life-changing therapies to people with rare genetic disorders. Prior to joining Rectify in November 2020, Janeta was VP, Head of Chemistry at Decibel Therapeutics, a biotech company dedicated discovering and developing transformative treatments to restore and improve hearing and balance. From 2010 to 2016 Janeta co-led drug discovery programs at Agios Pharmaceuticals that delivered clinical-stage molecules in the areas of cancer metabolism (co-inventor of Tibsovo®) and rare genetic metabolic disorders. Prior to joining Agios, Janeta spent 10 years at Merck Research Labs in Cambridge, MA (through merger with Schering-Plough) where she focused on small molecule drug discovery in oncology, inflammation and anti-viral therapeutic areas. Janeta holds a PhD in organic chemistry from Dartmouth College, and has more than 70 publications in peer-reviewed journals, patents, invited lectures and presentations. Over the years, she has been actively involved in the Gordon Research Conference and American Chemical Society and serves as the 2021 Chair of the Medicinal Chemistry GRC.